Skip to content

MANAGEMENT OF ARDHAVABHEDAKA THROUGH AYURVEDA

A COMPARATIVE STUDY OF EFFICACY OF BALA TAILA NASYA AND M-7 (HYPOTHETICAL DRUG) IN THE MANAGEMENT OF ARDHAVABHEDAKA W.S.R. TO MIGRAIN - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/067893
Enrollment
150
Registered
2024-05-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

None listed

Sponsors

UPGIASR RAU JODHPUR RAJASTHAN
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients’ between 16 to 60 years of age. 2.Patients with clinical signs and symptoms of Ardhavbhedaka. 3.Patients of either sex irrespective of their occupation, religion and socio-economic status. 4.Patients fit for Bala ail Nasya and Migro-7 Powder (hypothetical drug). 5. Patients willing to participate in trial and follow up with a signed consent.

Exclusion criteria

Exclusion criteria: 1.Secondary headaches caused by meningitis, tumors, encephalitis, head and neck trauma, trigeminal neuralgia, cervical spondylitis, refractive errors, sinusitis and other disorders of cranium, neck, eyes, ears, nose, sinuses, teeth etc. 2.Patients with complicated Migraine like status migrainosus, hemiplegic migraine and having any chronic debilitating disease with other neurological pathology. 3.Pregnant and lactating women. 4.Patients suffering from any other major systemic disorders e.g. tuberculosis, cancer, heart disease etc.

Design outcomes

Primary

MeasureTime frame
Improvement in clinical sign & symptoms of migraineTimepoint: 90 days

Secondary

MeasureTime frame
Improvement in quality of lifeTimepoint: 3 month

Countries

India

Contacts

Public ContactDr Pramod Kumar Mishra

Dr Sarwapalli Radhakrishnan Rajasthan Ayurveda University Jodhpur,

drpramodmishra4@gmail.com9001009793

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026